Loading
Every dated change on the records linked to HER2-mutant non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Confirmed response rate 71% in 75 previously treated patients naive to HER2-directed therapy; 48% after a HER2 antibody-drug conjugate; FDA accelerated approval August 2025.
ORR ~64%; accelerated approval Nov 2025.
A milestone in how this cancer is treated.
High response rate with durable responses in HER2-mutant non-small-cell lung cancer; accelerated approval in August 2022.
A milestone in how this cancer is treated.